[ONTX] Onconova Therapeutics, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 2.39 Change: 0.03 (1.27%)
Ext. hours: Change: 0 (0%)

chart ONTX

Refresh chart

Strongest Trends Summary For ONTX

ONTX is in the medium-term down -67% in 1 year and down -87% in 1 year and down -93% in 1 year. In the long-term down -95% in 3 years and up 30069% in 22 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drug candidates to treat cancer. Its clinical-stage product candidates include rigosertib intravenous that is in Phase III trials for higher risk myelodysplastic syndromes (MDS); rigosertib Oral, which is Phase II clinical trials for patients with transfusion-dependent lower risk MDS and in patients with head and neck cancers; and a combination of rigosertib Oral and azacitidine in a Phase 1/2 study of first-line MDS patients. The company?s clinical-stage product candidates also comprise ON 013105, a small molecule targeting an important regulatory protein, cyclin D1, which is found at elevated levels in cancer cells; and recilisib, a molecule with radiation protection properties has completed four Phase I clinical trials. In addition, its preclinical products consist of ON 1231320, an inhibitor of polo-like kinase 2; ON 123300, an inhibitor of the cell cycle and cancer cell metabolism

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -8.8% Sales Growth - Q/Q0% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-156.2% ROE-487.72% ROI
Current Ratio3.38 Quick Ratio Long Term Debt/Equity Debt Ratio0.92
Gross Margin Operating Margin-12282.7% Net Profit Margin-12279.7% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities Cash From Investing Activities Cash From Operating Activities-9.85 M Gross Profit
Net Profit-12.34 M Operating Profit-12.35 M Total Assets36.71 M Total Current Assets36.35 M
Total Current Liabilities10.76 M Total Debt Total Liabilities24.95 M Total Revenue110 K
Technical Data
High 52 week5.78 Low 52 week0.3 Last close0.3 Last change-24.58%
RSI26.62 Average true range0.06 Beta0.13 Volume18.76 K
Simple moving average 20 days-37.42% Simple moving average 50 days-66.09% Simple moving average 200 days-88.69%
Performance Data
Performance Week-16.19% Performance Month-64.92% Performance Quart-86.53% Performance Half-90.77%
Performance Year-92.55% Performance Year-to-date-85.7% Volatility daily10.4% Volatility weekly23.26%
Volatility monthly47.67% Volatility yearly165.14% Relative Volume157.7% Average Volume426.28 K
New High New Low

News

2020-08-03 11:52:03 | Onconova ONTX to Report Q2 Earnings: What's in the Offing?

2020-07-29 13:30:00 | Onconova Therapeutics Announces that the Required Number of Survival Events Has Been Reached for the Pivotal Phase 3 INSPIRE Trial Data Analysis

2020-07-27 08:00:00 | Onconova Therapeutics Submits Application for Rigosertib to Participate in Federally Funded Human Studies in COVID-19 Disease

2020-07-23 08:00:00 | Onconova Therapeutics Announces Publication of Preclinical Data Supporting Rigosertib’s Mechanism of Action as a Targeted Anticancer Therapy

2020-07-07 08:00:10 | Onconova Therapeutics Announces Publication of Phase 1 Results in Leukemia Research Exploring Oral Rigosertib in Combination with Azacitidine in Higher-Risk MDS

2020-06-23 10:43:02 | Onconova Initiates Phase I/IIa Study on Lung Cancer Candidate

2020-06-23 08:00:10 | Onconova Therapeutics Announces Participation in Noble Capital Markets Investor Webinar

2020-06-22 08:00:10 | Onconova Therapeutics Announces the Initiation of a Phase 1/2a Study of Rigosertib plus Nivolumab for the Treatment of KRAS+ Lung Adenocarcinoma

2020-06-12 08:00:10 | Onconova Therapeutics Announces Presentation at the 25th Congress of the European Hematology Association EHA

2020-06-08 08:00:10 | Onconova Therapeutics Announces Presentation at BIO Digital 2020

2020-05-28 09:44:06 | 3 “Strong Buy” Penny Stocks That Offer Massive Potential Gains

2020-05-18 11:33:58 | Edited Transcript of ONTX earnings conference call or presentation 14-May-20 8:30pm GMT

2020-05-14 16:05:10 | Onconova Therapeutics Provides Corporate Update and Reports First Quarter 2020 Financial Results

2020-05-11 08:00:10 | Onconova Therapeutics Announces Virtual Format for 2020 Annual Meeting of Stockholders

2020-05-07 08:00:10 | Onconova Therapeutics to Provide Corporate Update and First Quarter 2020 Earnings on May 14, 2020

2020-04-27 08:00:10 | Onconova Therapeutics Strengthens Board of Directors with Nomination of Life Sciences Industry Veteran

2020-04-07 06:40:00 | How 3 Philly-area biopharmaceutical firms are working through coronavirus challenges

2020-04-01 07:32:15 | Edited Transcript of ONTX earnings conference call or presentation 24-Mar-20 8:30pm GMT

2020-03-24 16:05:10 | Onconova Therapeutics Announces Completion of Enrollment of Phase 3 INSPIRE Trial, Provides a Corporate Update, and Reports 2019 Financial Results

2020-03-18 08:00:10 | Onconova Therapeutics to Provide Corporate Update and Full Year 2019 Financial Results

2020-03-13 09:46:01 | Will Onconova Therapeutics Continue to Surge Higher?

2020-03-02 09:54:02 | Onconova ONTX to Report Q4 Earnings: What's in Store?

2020-02-21 10:12:03 | The Zacks Analyst Blog Highlights: Onconova Therapeutics, Abeona Therapeutics, Proteostasis Therapeutics, Applied Therapeutics and Ennis

2020-02-20 08:45:01 | Onconova Therapeutics, Inc. ONTX Shares March Higher, Can It Continue?

2020-02-20 07:03:12 | US Dollar Flexes Muscles Against Other Currencies: 5 Winners

2020-02-19 11:19:04 | The Zacks Analyst Blog Highlights: Apple, Eagle Bancorp Montana, Onconova Therapeutics, Proteostasis Therapeutics and Abeona Therapeutics

2020-02-18 09:21:02 | Coronavirus to Hit Apple Sales: Invest in Domestic Producers

2020-02-18 08:00:10 | Onconova Therapeutics Announces Participation in Two Upcoming International Conferences

2020-02-10 08:00:10 | Onconova Therapeutics to Present Update at Noble Capital Markets’ Sixteenth Annual Investor Conference in Hollywood, FL

2020-02-04 08:00:10 | Onconova Therapeutics to Present Update at the 2020 BIO CEO & Investor Conference in New York City

2020-01-23 17:44:40 | Onconova shares rise after company regains rights to drug in China

2020-01-23 08:30:10 | Onconova Therapeutics Regains Rigosertib Rights in Greater China

2020-01-03 13:27:41 | Onconova Therapeutics, Inc. Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market

2020-01-02 13:48:43 | Bucks County biopharm firm plans $10M stock sale

2019-12-31 11:30:10 | Onconova Therapeutics, Inc. Announces $10 Million Registered Direct Offering Priced At-The-Market

2019-12-23 19:33:30 | Onconova Therapeutics, Inc. ONTX Is Burning These Hedge Funds

2019-12-19 13:44:55 | Onconova Therapeutics, Inc. Announces Closing Of $5.0 Million Registered Direct Offering Priced At-The-Market

2019-12-18 09:05:10 | Onconova Therapeutics, Inc. Announces $5.0 Million Registered Direct Offering Priced At-the-Market

2019-12-18 09:00:10 | Onconova Therapeutics Announces Exclusive License Agreement with Specialised Therapeutics for Rigosertib in Australia and New Zealand

2019-12-17 07:30:10 | Onconova Therapeutics and Pint Pharma Announce Brazilian Health Authority Approval for Initiating INSPIRE Trial with Intravenous Rigosertib in Higher-Risk Myelodysplastic Syndromes in Brazil

2019-12-10 15:07:58 | Onconova Therapeutics, Inc. Announces Closing of $5.0 Million Registered Direct Offering Priced At-the-Market

2019-12-09 09:00:10 | Onconova Therapeutics Announces Data on Genomic Profiles of Higher Risk Myelodysplastic Syndromes Patients Refractory to Azacitidine Therapy Enrolled into the Pivotal INSPIRE Trial and Updated Oral Rigosertib Data Informing a Potential Adaptive Clinical T

2019-12-09 08:00:10 | Onconova Therapeutics, Inc. Announces $5.0 Million Registered Direct Offering Priced At-the-Market

2019-12-07 08:35:07 | The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling

2019-12-06 08:49:10 | Benzinga Pro's Top 5 Stocks To Watch For Fri., Dec. 6, 2019: TSLA, ONTX, XHB, BIG, SFIX

2019-12-06 07:30:10 | Inceptua Medicines Access and Onconova Therapeutics Announce Pre-approval Access Collaboration for Rigosertib in Selected Countries Outside the US

2019-11-25 09:26:13 | Onconova Therapeutics, Inc. Announces Closing of $11.0 Million Public Offering

2019-11-22 14:46:50 | Bucks County biopharm firm enters into licensing deal, embarks on stock sale

2019-11-21 11:23:16 | Onconova Therapeutics, Inc. Announces $11.0 Million Public Offering

2019-11-21 10:16:12 | Onconova Therapeutics Announces Exclusive License Agreement with Knight Therapeutics for Rigosertib in Canada